[Treatment of prostatic neoplasms].
Early stage carcinoma of the prostate is curable. Not every patient must be treated because there are significant differences in the biologic activity of the tumors. This causes a sharp difference between morbidity and mortality rate in prostatic cancer. Besides the clinical staging morphological malignancy grading is the trend factor for the treatment that has to be chosen because it has shown to be a reasonable and feasable prognostic indicator.
D000315:Adrenalectomy; D000726:Androgen Antagonists; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002818:Cordotomy; D003534:Cyproterone / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D006801:Humans; D007016:Hypophysectomy; D008197:Lymph Node Excision; D008297:Male; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010166:Palliative Care; D010388:Pelvis; D011379:Prognosis; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000532:radiotherapy / Q000601:surgery*
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D004967:Estrogens; D003534:Cyproterone
Therapie des Prostatakarzinoms.